On December 4, 2017 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will webcast an analyst and investor event being held at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to discuss updated data and the development program for its BTK inhibitor zanubrutinib (BGB-3111) (Press release, BeiGene, DEC 4, 2017, View Source;p=RssLanding&cat=news&id=2320944 [SID1234522360]). ASH (Free ASH Whitepaper) will take place December 9-12, 2017 in Atlanta, GA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dial-in Information

Date & Time: Saturday, December 9, 2017, 8:00pm EST (Sunday, December 10, 2017, 9:00am China Standard Time)

Dial-In Numbers: 1-844-461-9930 or 1-478-219-0535 (US), 400-682-8609 or 800-870-0169 (China), 852-30114522 (Hong Kong), 65-66221010, 61-282239773, or 1-478-219-0535 (International)

Conference ID Number: 9086588

A live webcast and replay of the event will be available on BeiGene’s investor website, View Source The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-855-859-2056 or 1-404-537-3406 (US), 400-683-7185 (China), 852-30114541 (Hong Kong), 65-31583682, 61-282239792, or 1-855-859-2056 (International).